Laura Knoll, P.C.

Since joining Kirkland, Laura has been involved in the following matters:

• Akero Therapeutics in its sale to Novo Nordisk for up to $5.2 billion
• Sage Therapeutics in its $795 million sale to Supernus Pharmaceuticals

Prior to joining Kirkland, Laura was involved in the following representations:

• Chimerix in its $935 million sale to Jazz Pharmaceuticals
• Evergreen Theragnostics in its sale to Lantheus for up to $1 billion
• The special committee of the board of directors of R1 RCM in its sale to investment funds affiliated with TowerBrook Capital Partners and Clayton Dubilier & Rice for an enterprise value of $8.9 billion
• EyeBio in its sale to Merck for $1.3 billion up front and up to $1.7 billion in future milestone payments
• The special committee of the board of directors of EngageSmart in its $4 billion sale to Vista Equity Partners
• Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
• Intercept Pharmaceuticals in its sale to Alfasigma for approximately $800 million
• Iveric Bio in its $5.9 billion sale to Astellas
• Bottomline Technologies in its acquisition by Thoma Bravo for $2.6 billion
• Dicerna Pharmaceuticals in its sale to Novo Nordisk for $3.3 billion
• WeWork in its merger with BowX Acquisition Corp., a special purpose acquisition company, as a result of which WeWork would become a public company with an implied initial enterprise value of $9 billion
• Pandion Therapeutics in its sale to Merck for $1.8 billion
• Kelso & Company in the acquisition of Refresh Mental Health from Lindsay Goldberg, and in its subsequent sale of Refresh Mental Health to Optum, a division of UnitedHealthcare
• Ionis Pharmaceuticals in its acquisition of the remaining outstanding stake of Akcea Therapeutics for $500 million
• CerSci Therapeutics in its sale to ACADIA Pharmaceuticals for up to $939.5 million
• ArQule in its sale to Merck for $2.7 billion
• WeWork in an $8 billion transaction in which SoftBank provided financing to the company and proposed acquiring a majority of its outstanding shares through a tender offer
• Alder in its sale to Lundbeck for up to $1.95 billion
• Array BioPharma in its $11.4 billion acquisition by Pfizer
• Highbridge Capital Management in its acquisition of assets from Pernix Therapeutics, structured as a Chapter 11 credit bid
• WeWork in its $6 billion investment from SoftBank
• United Natural Foods in its acquisition of SUPERVALU for $2.9 billion, including assumption of outstanding debt and liabilities
• Hasbro in its $522 million acquisition of Saban Brands’ Power Rangers and other entertainment assets
• Kelso & Company and affiliates of Blue Wolf Capital Partners in connection with the acquisition of Jordan Health Services from Palladium Equity Partners, and Kelso in connection with the concurrent merger of Jordan Health Services with Great Lakes Caring and National Home Health Care under a combined entity jointly owned with affiliates of Blue Wolf
• WeWork in its $4.4 billion investment from SoftBank Group and SoftBank Vision Fund
• Ultragenyx Pharmaceutical in its successful topping bid for Dimension Therapeutics
• Tobira Therapeutics, Inc. in its sale to Allergan for up to $1.7 billion
• Qlik Technologies Inc. in its $3 billion acquisition by Thoma Bravo, LLC
• EMC Corporation in its $67 billion acquisition by Denali Holding Inc., the parent company of Dell Inc.
• Banco BTG Pactual S.A. in its $1.7 billion acquisition of BSI SA from Assicurazioni Generali S.p.A. and sale of BSI SA to EFG International AG
• Valeant Pharmaceuticals International, Inc. in its $1 billion acquisition of Sprout Pharmaceuticals, Inc., plus a share of future profits based on achievement of milestones
• Dendreon Corporation in its Chapter 11 filing and proposed restructuring of $620 million of convertible notes and in its sale of assets to Valeant Pharmaceuticals International, Inc. for $495 million